Zfra induction of memory anticancer response via a novel immune cell

Wan-Pei Su; Wan-Jan Wang; Chun-I Sze; Nan-Shan Chang

doi:10.1080/2162402X.2016.1213935

Zfra induction of memory anticancer response via a novel immune cell

Oncoimmunology. 2016 Jul 28;5(9):e1213935. doi: 10.1080/2162402X.2016.1213935. eCollection 2016.

Authors

Wan-Pei Su¹, Wan-Jan Wang¹, Chun-I Sze², Nan-Shan Chang³

Affiliations

¹ Institute of Molecular Medicine, National Cheng Kung University , Tainan, Taiwan, ROC.
² Department of Cell Biology and Anatomy, National Cheng Kung University , Tainan, Taiwan, ROC.
³ Institute of Molecular Medicine, National Cheng Kung University, Tainan, Taiwan, ROC; Center of Infectious Disease and Signaling Research, National Cheng Kung University, Tainan, Taiwan, ROC; Advanced Optoelectronic Technology Center, National Cheng Kung University, Tainan, Taiwan, ROC; Graduate Institute of Biomedical Sciences, College of Medicine, China Medical University, Taichung, Taiwan, ROC.

Abstract

When naive mice receive short Zfra peptides via tail vein injections, they develop lifetime resistance to growth of many cancer xenografts, due to activation of a novel spleen memory Hyal-2⁺ CD3^- CD19^- Z lymphocyte. In vitro education of spleen cells with Zfra activates Z cell for conferring memory anticancer response in vivo.

Keywords: Zfra; Hyal-2+ CD3- CD19-; Hyaluronidase Hyal-2; Z lymphocyte; memory anticancer response.

Publication types

Research Support, U.S. Gov't, Non-P.H.S.
Research Support, Non-U.S. Gov't